Biohaven Therapeutics
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Biohaven Therapeutics sits in the top decile of US sponsors by registered trial count (#886 of 15,742 sponsors by registered trial count).
Biohaven Therapeutics: 16 sponsored US clinical trials, 8 recruiting.
Biohaven Therapeutics sponsors 16 registered US clinical trials on ClinicalTrials.gov, 8 of them currently recruiting, and 4 completed. 1 of these trials are in Phase 3-4 (later-stage) and 14 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Focal Epilepsy, with 2 trials.
Top-decile sponsor footprint
Biohaven Therapeutics ranks in the top decile of sponsors by registered trial count (#886 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
16 total, page 1 of 1
Study to Determine if BHV-1300 is Effective and Safe in Adults With Graves' Disease
NCT07661056
Study of BHV-1300 in Graves' Disease
NCT06980649
Study of BHV-1400 in IgA Nephropathy
NCT07054684
A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease
NCT06976268
A Phase 1 Study of BHV-1530 in Advanced Solid Tumors
NCT06874335
Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
NCT06309966
A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors
NCT06384807
A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
NCT06132893
Taldefgrobep Alfa in Adults With Overweight and Obesity
NCT07281495
A Study to Determine if BHV-7000 is Effective and Safe in Adults With Idiopathic Generalized Epilepsy With Generalized Tonic-clonic Seizures
NCT06425159
Real-World Data Study of Troriluzole-Treated Patients With Spinocerebellar Ataxia (SCA) Compared to a Matched Natural History Control
NCT06529146
Efficacy and Safety Trial of BHV-2100 for the Acute Treatment of Migraine
NCT06603623
Long-term Safety Study of BHV-7000 in Participants With Major Depressive Disorder (MDD)
NCT06423781
BHV-7000 Open-Label Extension Bipolar Mania Study
NCT06423794
Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression
NCT06419608
BHV-7000 Acute Treatment of Bipolar Mania
NCT06419582
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 10 |
| Phase 3 | 1 |
Therapeutic Areas
What is open in the Biohaven Therapeutics pipeline
8 recruiting of 16 indexed (50% open); 4 completed (25%).
Phase mix: 1 late (III/IV) vs 14 early (I/II) (early-phase heavy).
Top condition: Focal Epilepsy (2 trials), 8 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Biohaven Therapeutics: open-pipeline peers nationwide
Peers matched on 16 registered trials and 50% open enrollment, not the therapeutic-area sidebar.
Biohaven Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 16 trials (± recruiting share)
- Accelerated Community Oncology Research Network · 16 trials · 0% recruiting
- Altimmune · 16 trials · 6% recruiting
- American University · 16 trials · 13% recruiting
- Anthera Pharmaceuticals · 16 trials · 0% recruiting
Sponsors near 50% open enrollment (± trial volume)
- 1200 Pharma · 50% recruiting · 2 trials
- 1ST Biotherapeutics · 50% recruiting · 2 trials
- 3ive Labs · 50% recruiting · 2 trials
- 60 Degrees Pharmaceuticals · 50% recruiting · 4 trials
Related
What to do with this Biohaven Therapeutics page
16 registered trials is a research-attention snapshot, not an endorsement of Biohaven Therapeutics or any single study.
- 8 of Biohaven Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Focal Epilepsy is the condition Biohaven Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Focal Epilepsy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Biohaven Therapeutics pipeline card: 16 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.